Article Type
Original Study
Subject Area
Anaesthesiology
Abstract
Introduction : - Immune response may be affected by anesthesia and sedation. In anesthesia, the immue response is temporary as anesthesia is used for short time. However, the immune response more obvious in critical illness patients because of long time of sedation. Diprivan and dormicum are two commonly used medications for sedation and analgesia in critical care unit patients. Dipravan is a good medication for sedation in the surgical care unit. Dormicum in the surgical care unit, usually producing prolonged time of sedation when used for long time in surgical care unit. Patients and methods: - This article was done on 60 patients undergoing vascular and abdominal operation who were to use sedation for long time more than one day post – operative. Patients were divided to one of two classes (each class = 30 0ne). class A. Patients use diprivan. classs B. Patients use dormicum. Results: - no significant variation between both classes as regard age, sex, weigth , surgical diagnosis , sedation score , ventilation and PO2 with significant decrease in PH and PCO2 in class B . Concerning heart rate and mean blood pressure there were significant decrease in class B. As regard the immune response of serum tumor necrosis factor- a and interferon- g and C-reactive protein showed significant increase in class A 24hours post-infusion while no significant change in group B.Conclusion: - After 24 hours continuous infusion, propofol stimulated, the production of the pro- inflammatory cytokines TNF- a , Creactive protein and interferon - g . While dormicum failed to do so.
IRB Number
NHI000564
Keywords
Diprivan, dormicum, immune response
Recommended Citation
Soliman, Ashraf Abd El Hameed; El hakeem, Wael Abd elateif; and Abdellatif, Raghad S.
(2023)
"The immune response to long term administration of Dipravan compare to dormicum in surgical care unit,"
Journal of Medicine in Scientific Research: Vol. 6:
Iss.
2, Article 1.
DOI: https://doi.org/10.59299/2537-0928.1000
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.